Prostate cancer remains the most commonly diagnosed cancer among males in the U.S. next to skin cancer. It affects 1 out of 7 male Americans, and is ranked the second most common cause of death among men.
While the American Cancer Society reveals there are more than 2.5 million prostate cancer survivors today and that most who are diagnosed do not die from it, it is still considered a serious and fatal disease, especially when treated late as advanced stages may build resistance to available drugs.
A group of scientists from Baylor College of Medicine recently completed a study on mice that suggests the key to treating resistant advanced prostate cancer lies in developing an androgen blocker for a nuclear receptor coactivator dubbed as NCoA2 or SRC-2. Their findings, titled "Androgen deprivation–induced NCoA2 promotes metastatic and castration-resis